These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25533449)

  • 1. [Consensus document on the treatment of dyslipidemia in diabetes].
    Hormigo-Pozo A; Mancera-Romero J; Perez-Unanua MP; Alonso-Fernandez M; Lopez-Simarro F; Mediavilla-Bravo JJ;
    Semergen; 2015 Mar; 41(2):89-98. PubMed ID: 25533449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic Dyslipidemia Review: An Update on Current Concepts and Management Guidelines of Diabetic Dyslipidemia.
    Dake AW; Sora ND
    Am J Med Sci; 2016 Apr; 351(4):361-5. PubMed ID: 27079341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future perspectives of the pharmacological management of diabetic dyslipidemia.
    Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management.
    Chehade JM; Gladysz M; Mooradian AD
    Drugs; 2013 Mar; 73(4):327-39. PubMed ID: 23479408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
    Anabtawi A; Moriarty PM; Miles JM
    Curr Cardiol Rep; 2017 Jul; 19(7):62. PubMed ID: 28528456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets.
    Ng DS
    Can J Diabetes; 2013 Oct; 37(5):319-26. PubMed ID: 24500559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
    Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
    Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
    Taskinen MR; Borén J
    Atherosclerosis; 2015 Apr; 239(2):483-95. PubMed ID: 25706066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in lipid testing and management in patients with diabetes mellitus.
    Vasudevan MM; Ballantyne CM
    Endocr Pract; 2009; 15(6):641-52. PubMed ID: 19625239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.
    Vavlukis M; Kedev S
    Curr Pharm Des; 2018; 24(4):427-441. PubMed ID: 29283060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
    Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.
    Wanner C; Krane V
    Kidney Blood Press Res; 2011; 34(4):209-17. PubMed ID: 21691123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
    Pintó X
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():35-9. PubMed ID: 25043546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid Management in Diabetes with a Focus on Emerging Therapies.
    Hoe E; Hegele RA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S183-90. PubMed ID: 26653256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipids-Diagnosis and therapy in diabetes mellitus (Update 2023)].
    Wascher TC; Paulweber B; Toplak H; Saely CH; Drexel H; Föger B; Hoppichler F; Stulnig T; Stingl H; Clodi M;
    Wien Klin Wochenschr; 2023 Jan; 135(Suppl 1):157-160. PubMed ID: 37101037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.